Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B
Objective To analyze the clinical features of HBeAg and HBeAb double-positive patients with chronic hepatitis B, and explore the efficacy and outcomes of different antiviral regimens. Methods A total of 158 HBeAg and HBeAb double-positive patients with chronic hepatitis B who met the antiviral treat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Third Military Medical University
2022-01-01
|
| Series: | Di-san junyi daxue xuebao |
| Subjects: | |
| Online Access: | http://aammt.tmmu.edu.cn/Upload/rhtml/202107114.htm |
| _version_ | 1818298500631232512 |
|---|---|
| author | AN Xuan LIU Shuhong XIA Lina WU Guicheng XIANG Yi HU Peng LUO Huan |
| author_facet | AN Xuan LIU Shuhong XIA Lina WU Guicheng XIANG Yi HU Peng LUO Huan |
| author_sort | AN Xuan |
| collection | DOAJ |
| description | Objective To analyze the clinical features of HBeAg and HBeAb double-positive patients with chronic hepatitis B, and explore the efficacy and outcomes of different antiviral regimens. Methods A total of 158 HBeAg and HBeAb double-positive patients with chronic hepatitis B who met the antiviral treatment criteria were selected from Chongqing Three Gorges Hospital from 2014 to 2018. They were divided into entecavir treatment group (n=52), interferon treatment group (n=49), and control group (without antiviral treatment, n=57) according to the actual treatment regimen, and were followed up for 48 weeks. The efficacy and outcomes of patients were observed and compared among different groups. Results Baseline distribution of HBeAg and HBeAb: among 158 HBeAg/HBeAb double positive chronic hepatitrs B patients, 79 patients had HBeAg≥10, and 79 patieats had HBeAg < 10, each accounting for 50%; HBV DNA level was 4.77±1.23 Lg. Antiviral efficacy: the decrease of HBV DNA level, the HBV DNA negative conversion rate, and the normalization rate of ALT were all better in the entecavir group than the interferon group (P < 0.05), while the decline of HBeAg and HBeAb levels, as well as the HBeAg negative conversion rate were greater in the interferon group (P < 0.05). Clinical outcomes: the proportion of patients who became HBeAg negative or only presented HBsAg and HBcAb positive was significantly larger in the antiviral groups as compared with the control group (P < 0.05), while the control group showed higher proportion of continuous "double-positive" (P < 0.05). In addition, the decrease range of HBeAg-Lg/HBeAb ratio before and after treatment had the greatest value in predicting HBeAg negative conversion. Conclusion For HBeAg and HBeAb double-positive patients with chronic hepatitis B, interferon treatment shows greater advantage in HBeAg negative conversion. Monitoring the decline of HBeAg-Lg/HBeAb is helpful to predict clinical outcome in the double-positive patients. |
| first_indexed | 2024-12-13T04:36:19Z |
| format | Article |
| id | doaj.art-35d83c4f25754a7d8beebdd87edbe1d0 |
| institution | Directory Open Access Journal |
| issn | 1000-5404 |
| language | zho |
| last_indexed | 2024-12-13T04:36:19Z |
| publishDate | 2022-01-01 |
| publisher | Editorial Office of Journal of Third Military Medical University |
| record_format | Article |
| series | Di-san junyi daxue xuebao |
| spelling | doaj.art-35d83c4f25754a7d8beebdd87edbe1d02022-12-21T23:59:25ZzhoEditorial Office of Journal of Third Military Medical UniversityDi-san junyi daxue xuebao1000-54042022-01-0144216216710.16016/j.2097-0927.202107114Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis BAN Xuan0LIU Shuhong1XIA Lina2WU Guicheng3XIANG Yi4HU Peng5LUO Huan6Department of Hepatology, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, 404000Department of Hepatology, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, 404000;Department of Hepatology, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, 404000;Department of Hepatology, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, 404000;Department of Hepatology, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, 404000;Department of Hepatobiliary Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Hepatobiliary Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Objective To analyze the clinical features of HBeAg and HBeAb double-positive patients with chronic hepatitis B, and explore the efficacy and outcomes of different antiviral regimens. Methods A total of 158 HBeAg and HBeAb double-positive patients with chronic hepatitis B who met the antiviral treatment criteria were selected from Chongqing Three Gorges Hospital from 2014 to 2018. They were divided into entecavir treatment group (n=52), interferon treatment group (n=49), and control group (without antiviral treatment, n=57) according to the actual treatment regimen, and were followed up for 48 weeks. The efficacy and outcomes of patients were observed and compared among different groups. Results Baseline distribution of HBeAg and HBeAb: among 158 HBeAg/HBeAb double positive chronic hepatitrs B patients, 79 patients had HBeAg≥10, and 79 patieats had HBeAg < 10, each accounting for 50%; HBV DNA level was 4.77±1.23 Lg. Antiviral efficacy: the decrease of HBV DNA level, the HBV DNA negative conversion rate, and the normalization rate of ALT were all better in the entecavir group than the interferon group (P < 0.05), while the decline of HBeAg and HBeAb levels, as well as the HBeAg negative conversion rate were greater in the interferon group (P < 0.05). Clinical outcomes: the proportion of patients who became HBeAg negative or only presented HBsAg and HBcAb positive was significantly larger in the antiviral groups as compared with the control group (P < 0.05), while the control group showed higher proportion of continuous "double-positive" (P < 0.05). In addition, the decrease range of HBeAg-Lg/HBeAb ratio before and after treatment had the greatest value in predicting HBeAg negative conversion. Conclusion For HBeAg and HBeAb double-positive patients with chronic hepatitis B, interferon treatment shows greater advantage in HBeAg negative conversion. Monitoring the decline of HBeAg-Lg/HBeAb is helpful to predict clinical outcome in the double-positive patients.http://aammt.tmmu.edu.cn/Upload/rhtml/202107114.htmhbeag/hbeab double positiveclinical characteristicsentecavirinterferonefficacyoutcome |
| spellingShingle | AN Xuan LIU Shuhong XIA Lina WU Guicheng XIANG Yi HU Peng LUO Huan Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B Di-san junyi daxue xuebao hbeag/hbeab double positive clinical characteristics entecavir interferon efficacy outcome |
| title | Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B |
| title_full | Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B |
| title_fullStr | Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B |
| title_full_unstemmed | Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B |
| title_short | Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B |
| title_sort | efficacy and clinical outcomes of different antiviral regimens in hbeag hbeab double positive patients with chronic hepatitis b |
| topic | hbeag/hbeab double positive clinical characteristics entecavir interferon efficacy outcome |
| url | http://aammt.tmmu.edu.cn/Upload/rhtml/202107114.htm |
| work_keys_str_mv | AT anxuan efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT liushuhong efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT xialina efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT wuguicheng efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT xiangyi efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT hupeng efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb AT luohuan efficacyandclinicaloutcomesofdifferentantiviralregimensinhbeaghbeabdoublepositivepatientswithchronichepatitisb |